Medication info
Presta Capsule 75 mg (Pregabalin)

Presta Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Bainex Co., Ltd.
Appearance
Hard capsules with a reddish-brown upper part and a white lower part containing white or pale yellow powder.
Packaging
100 capsules/bottle, 30 capsules/bottle
Approval status
Active

MFDS item code 201109285 · Approved 2011.10.31 · Insurance code 643103440

Summary

Main use
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys unchanged after passing through the systemic circulation. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For females, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Bainex Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine helps treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive therapy for partial seizures in epilepsy, with or without secondary generalization. Additionally, it is effective in alleviating symptoms of fibromyalgia. It is used for the treatment of various neurological disorders to help improve the patient's condition.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys unchanged after passing through the systemic circulation. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For females, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so careful monitoring for abnormal changes in mood or behavior is necessary during treatment. Avoid administration if there is hypersensitivity to this medication or if specific genetic conditions such as lactose intolerance are present. Diabetic patients may need to adjust the dosage of blood sugar control medications due to weight gain. If symptoms of angioedema occur, discontinuation of the medication should be immediate, and caution is necessary for the elderly due to the risk of injury from dizziness or drowsiness. Blurred vision or changes in eyesight may occur, and these symptoms may improve upon discontinuation of the medication. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon discontinuation, so consultation with medical staff is necessary. Patients with a history of substance abuse should be cautious due to the risk of misuse, and monitoring for signs of misuse or dependence is required. Patients with decreased kidney function may require dose adjustments. Patients with heart disease should use this medication carefully due to the risk of heart failure during treatment. Co-administration with opioid analgesics may increase the risk of central nervous system depression, so caution is warranted. During early pregnancy, there may be a risk of fetal malformations; therefore, use during pregnancy should be avoided, and women of childbearing age should employ effective contraceptive methods. During lactation, this medication can be transmitted to breast milk and may affect infants, so consideration should be given to discontinuing breastfeeding or the medication. Caution is needed when driving or operating machinery due to the risk of accidents caused by dizziness and drowsiness. Severe skin reactions may occur, so immediate discontinuation is necessary if any skin abnormal symptoms arise. In cases of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and treatment such as hemodialysis may be necessary. This medication should be kept out of reach of children, and transferring it to other containers may reduce its quality, so caution is needed.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal mood and behavior changes, angioedema, facial swelling, perioral swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, insomnia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, parageusia, restlessness, anxiety, mood swings, emotional blunting, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, inability to control impulses, apathy, ataxia, movement coordination disorder, balance disorder, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonus, decreased reflexes, movement disorders, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremors, syncope, stupor, hypokinesia, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, loss of indirect vision, visual disturbances, visual field loss, photophobia, dry eyes, eye swelling, decreased visual acuity, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, vibration-induced changes in depth perception, strabismus, brightness perception, vertigo, auditory hyperesthesia, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, nasal bleeding, cough, nasal congestion, rhinitis, snoring, throat tightness, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falling, a drunken feeling, altered sensation, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorders, drowsiness, confused state, depression, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and humidity, preferably at room temperature between 15 and 30 degrees Celsius. Storing it this way helps maintain the medication's efficacy and ensures safe use.

Appearance and packaging

Appearance

Hard capsules with a reddish-brown upper part and a white lower part containing white or pale yellow powder.

Package unit

100 capsules/bottle, 30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.